Modulight Investor Contacts: Ulla Haapanen ulla.haapanen@modulight.com (408) 218-7960 Modulight Media Contacts: Zoe Ylöniemi zoe.yloniemi@modulight.com (408) 239-3488 Bausch + Lomb Investor Contacts: Arthur Shannon/Allison Ryan arthur.shannon@bausch.com allison.ryan@bausch.com (877) 354-3705 (toll free); (908) 927-0735 Bausch + Lomb Media Contacts: Lainie Keller/Kristy Marks lainie.keller@bausch.com kristy.marks@bausch.com (908) 927-1198; (908) 927-0683 Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection) VAUGHAN, Ontario and TAMPERE, Finland, Feb. 1, 2023 – Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – December 2022 This month’s research spotlight goes to H. Wakiyama, H. Kobayashi, et al. at National Cancer Institute, USA. Their study, published in Cancer Immunology Research journal, looked into immunological mechanisms behind hyperprogressive disease. Immune checkpoint inhibitors, despite being a major success story in the field of cancer therapy, unfortunately lead to this rapid progression of cancer in some patients, for yet poorly understood reasons. To study this, the research team partially depleted cytotoxic T cells by photoimmunotherapy, using CD8-targeted Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – November 2022 This month’s Spotlight goes to Susumu Yamashita et al. for promising findings on novel light-based therapy for breast cancer treatment, published in a journal Cancer Medicine. Their teams at Olympus and Tokyo University of Agriculture and Technology developed trastuzumab-conjugated photo-absorber (Tra-IR700) which targets HER2-positive breast cancer cells. This treatment strategy is particularly relevant, since HER2 biomarker is associated with poor survival of breast cancer patients and often has intrinsic or acquired resistance to standard trastuzumab therapy. Especially for these patients, Tra-IR700 activated with Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – October 2022 This month’s laser sharp nomination goes to Takuya Osada‘s team at Duke University Medical Center. Their impressive results on novel immunotherapy combination strategy for breast cancer was published in the Journal for ImmunoTherapy of Cancer. The team combined immune checkpoint blockage with HSP90-targeted light therapy using ML7710 medical laser. This combination resulted in strong activation of antitumor immunity and prolonged survival in syngeneic breast cancer models. Impressively, adding immune checkpoint blockers even resulted in an increased antitumor activity elsewhere, outside the local light-treated area, showing potential Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – September 2022 Mesothelioma is a form of pleural cancer originating primarily from asbestos exposure. There is currently no curative treatment available for this cancer and its prevalence is on the rise, hence new treatment options are urgently needed. To answer this need, Professors Timothy C. Zhu and Keith Cengel with their teams at University of Pennsylvania have for several years studied intraoperative photodynamic therapy, where photosensitive drug is locally activated with laser light, as a potential new adjunctive treatment for this aggressive disease. Their most recent Continue reading →

Customer case Faculty of Pharmacy at University of Helsinki is specialized in top-level pharmaceutical research. Multidisciplinary research fields include clinical pharmacy, experimental drugs, nanomedicines, and pharmaceutical drug design. Drug delivery unit led by Professor Arto Urtti focuses on design and testing of advanced drug delivery systems especially for ocular indications. Light is studied as an important tool to control the drug delivery to the target tissues. Modulight products: ML6600 (810 nm) + Modulight in vitro illumination kit (MLAKIT) Professor Arto Urtti   Senior Pharmaceutical Researcher Tatu Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – August 2022 Impressive research on head & neck cancer was published by Obaid Lab for molecular imaging and optical nanotherapeutics, at University of Texas, Dallas. The group used Modulight’s ML6500 for a subtherapeutic modulation of tumor microenvironment of H&N. This significantly improved delivery of molecular imaging agent to the tumors as well as improved diagnostic accuracy in detecting tumor tissue by fluorescence. Since incomplete resection and consequent recurrences are common problem with current H&N cancer treatment, this discovery answers unmet Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – July 2022 Modulight congratulates Dr. Makoto Mitsunaga et al. Jikei University School of Medicine for publishing their promising results in Communications Biology journal. The team developed a next-generation light-based approach to tackle pathogens, called photoimmuno-antimicrobial strategy (PIAS). This technology was shown to eliminate a broad spectrum of different classes of pathogens, such as viruses, fungi, and bacteria. Unlike antibiotics, PIAS was also effective against drug-resistant pathogens and didn’t damage natural, beneficial microbiota in the host’s tissues. As COVID-19 pandemic and Continue reading →